NCT02601612View on ClinicalTrials.gov

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 26, 2018

Study Completion Date

April 26, 2018

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

D46cpΔM2-2 vaccine

Delivered as nose drops

BIOLOGICAL

Placebo

Delivered as nose drops

Trial Locations (1)

21205

Johns Hopkins Bloomberg School of Public Health, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02601612 - Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children | Biotech Hunter | Biotech Hunter